Oslo, Norway

Reidar Oftebro

This inventor holds 1 USPTO granted patent. Top assignee: Nyegaard & Co A/s. Active years: 1983.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Reidar Oftebro. Retrieved from https://idiyas.com/inventor/reidar-oftebro-gtdyimnv

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 13(Granted Patents)


Company Filing History:


Years Active: 1983

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Reidar Oftebro: Innovator in Pharmacological Compounds

Introduction

Reidar Oftebro is a notable inventor based in Oslo, Norway. He has made significant contributions to the field of pharmacology through his innovative research and development of novel compounds. His work focuses on creating derivatives that have potential therapeutic applications.

Latest Patents

Reidar Oftebro holds a patent for "5-Halopyrimid-2-ones," which describes novel derivatives of pyrimid-2-one with interesting pharmacological properties. These compounds have been found to be useful in controlling and inhibiting the metaphase of malignant tumors and leukemias. The patent also outlines processes for preparing these novel compounds and pharmaceutical compositions that contain them.

Career Highlights

Reidar Oftebro is associated with Nyegaard & Co. A/S, where he has been instrumental in advancing research in pharmacological compounds. His work has contributed to the understanding and development of treatments for serious health conditions.

Collaborations

Throughout his career, Reidar has collaborated with notable colleagues, including Mikkel J Gacek and Soren Laland. These collaborations have further enhanced the impact of his research in the field.

Conclusion

Reidar Oftebro's innovative work in pharmacological compounds demonstrates his commitment to advancing medical science. His contributions have the potential to significantly impact the treatment of malignant tumors and leukemias.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…